SCHEMBL17386262

SCHEMBL17386262

COC(=O)c1ccccc1C=Cc1cc(C)cc(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.52
BCR P11274 3/20 0.52
ABCB1 P08183 2/20 0.52
BACE1 P56817 1/20 0.47
CYP19A1 P11511 1/20 0.47
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17386261 1.00 ABL1 (0.52) ABL1BCRABCB1BACE1CYP19A1
SCHEMBL17429660 0.90 BACE1 (0.52) ABL1BCRABCB1BACE1HSD17B10
SCHEMBL28089618 0.84 NFE2L2 (0.61) BACE1NR1H3CYP1A2CYP1A1CYP1B1
SCHEMBL5332771 0.82 BACE1 (0.59) BACE1MEN1MAPTKMT2ASMN1; SMN2
SCHEMBL5343618 0.82 BACE1 (0.59) BACE1MEN1MAPTKMT2ASMN1; SMN2
SCHEMBL69553 0.80 BACE1 (0.60) BACE1HSD17B10KDM4EALDH1A1HPGD
SCHEMBL69552 0.80 BACE1 (0.60) BACE1HSD17B10KDM4EALDH1A1HPGD
SCHEMBL22887290 0.78 PLA2G2A (0.48) BACE1HSD17B10KDM4EALDH1A1MEN1
SCHEMBL29496380 0.78 PLA2G2A (0.48) BACE1HSD17B10KDM4EALDH1A1MEN1
SCHEMBL29227737 0.78 BACE1 (0.61) BACE1HSD17B10KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108017603-B Tricyclic compounds and uses thereof 株式会社蒂奥姆生物 2021-07-23 CN disclosed
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 EP disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 ABL1 4410/4885BCR 3407/4885ABCB1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.